Novartis has presented data showing that its chronic obstructive pulmonary disease drug Ultibro was superior in reducing flare-ups compared to GlaxoSmithKline’s blockbuster Seretide. Novartis has ...
Novartis has presented data showing that its chronic obstructive pulmonary disease drug Ultibro was superior in reducing flare-ups compared to GlaxoSmithKline’s blockbuster Seretide. Novartis has ...
TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (“Sosei”)(TOKYO:4565) confirms that Novartis Pharma K.K. launched once-daily Ultibro ® Inhalation Capsules (“Ultibro ® ”; glycopyrronium / indacaterol), ...
Novartis announced the New England Journal of Medicine publication of the head-to-head FLAME study comparing the efficacy of once-daily Ultibro Breezhaler ...
QUANTIFY study met primary endpoint demonstrating non-inferiority of Ultibro®Breezhaler® vs tiotropium 18 mcg plus formoterol 12 mcg in improving health-related quality of life outcomes[1],[2] ...
Please provide your email address to receive an email when new articles are posted on . Outcomes may vary among different fixed-dose combination inhalers for COPD ...
A new study suggests COPD patients experience improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid containing combination therapies to Novartis’ ...
Novartis has signed its second ‘connected inhaler’ research pact in just over a year, this time agreeing a European tie-up with Propeller Health. It adds to the pharma firm’s 2016 deal with Qualcomm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback